» Articles » PMID: 16359544

Introduction of in Vitro Transcribed ENO1 MRNA into Neuroblastoma Cells Induces Cell Death

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2005 Dec 20
PMID 16359544
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neuroblastoma is a solid tumour of childhood often with an unfavourable outcome. One common genetic feature in aggressive tumours is 1p-deletion. The alpha-enolase (ENO1) gene is located in chromosome region 1p36.2, within the common region of deletion in neuroblastoma. One alternative translated product of the ENO1 gene, known as MBP-1, acts as a negative regulator of the c-myc oncogene, making the ENO1 gene a candidate as a tumour suppressor gene.

Methods: Methods used in this study are transfection of cDNA-vectors and in vitro transcribed mRNA, cell growth assay, TUNEL-assay, real-time RT-PCR (TaqMan) for expression studies, genomic sequencing and DHPLC for mutation detection.

Results: Here we demonstrate that transfection of ENO1 cDNA into 1p-deleted neuroblastoma cell lines causes' reduced number of viable cells over time compared to a negative control and that it induces apoptosis. Interestingly, a similar but much stronger dose-dependent reduction of cell growth was observed by transfection of in vitro transcribed ENO1 mRNA into neuroblastoma cells. These effects could also be shown in non-neuroblastoma cells (293-cells), indicating ENO1 to have general tumour suppressor activity. Expression of ENO1 is detectable in primary neuroblastomas of all different stages and no difference in the level of expression can be detected between 1p-deleted and 1p-intact tumour samples. Although small numbers (11 primary neuroblastomas), there is some evidence that Stage 4 tumours has a lower level of ENO1-mRNA than Stage 2 tumours (p = 0.01). However, mutation screening of 44 primary neuroblastomas of all different stages, failed to detect any mutations.

Conclusion: Our studies indicate that ENO1 has tumour suppressor activity and that high level of ENO1 expression has growth inhibitory effects.

Citing Articles

Unveiling Tumorigenesis Mechanisms and Drug Therapy in Neuroblastoma by Mass Spectrometry Based Proteomics.

Ren K, Wang Y, Zhang M, Tao T, Sun Z Children (Basel). 2024; 11(11).

PMID: 39594898 PMC: 11593200. DOI: 10.3390/children11111323.


Long non-coding RNA NMRAL2P promotes glycolysis and reduces ROS in head and neck tumors by interacting with the ENO1 protein and promoting GPX2 transcription.

Nie Q, Cao H, Yang J, Liu T, Wang B PeerJ. 2023; 11:e16140.

PMID: 37810778 PMC: 10552744. DOI: 10.7717/peerj.16140.


ENO1 expression and Erk phosphorylation in PDAC and their effects on tumor cell apoptosis in a hypoxic microenvironment.

Sun H, Mo J, Cheng R, Li F, Li Y, Guo Y Cancer Biol Med. 2022; 19(11).

PMID: 36476328 PMC: 9724225. DOI: 10.20892/j.issn.2095-3941.2022.0451.


ENO1 and Cancer.

Huang C, Sun Y, Lv L, Ping Y Mol Ther Oncolytics. 2022; 24:288-298.

PMID: 35434271 PMC: 8987341. DOI: 10.1016/j.omto.2021.12.026.


Severe pantothenic acid deficiency induces alterations in the intestinal mucosal proteome of starter Pekin ducks.

Tang J, Feng Y, Zhang B, Wu Y, Guo Z, Liang S BMC Genomics. 2021; 22(1):491.

PMID: 34193047 PMC: 8246668. DOI: 10.1186/s12864-021-07820-x.


References
1.
Maris J, Matthay K . Molecular biology of neuroblastoma. J Clin Oncol. 1999; 17(7):2264-79. DOI: 10.1200/JCO.1999.17.7.2264. View

2.
Kaghad M, Bonnet H, Yang A, Creancier L, Biscan J, Valent A . Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997; 90(4):809-19. DOI: 10.1016/s0092-8674(00)80540-1. View

3.
Feo S, Arcuri D, Piddini E, Passantino R, Giallongo A . ENO1 gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1 (MBP-1). FEBS Lett. 2000; 473(1):47-52. DOI: 10.1016/s0014-5793(00)01494-0. View

4.
Ejeskar K, Abel F, Sjoberg R, Backstrom J, Kogner P, Martinsson T . Fine mapping of the human preprocortistatin gene (CORT) to neuroblastoma consensus deletion region 1p36.3-->p36.2, but absence of mutations in primary tumors. Cytogenet Cell Genet. 2000; 89(1-2):62-6. DOI: 10.1159/000015566. View

5.
Ejeskar K, Sjoberg R, Abel F, Kogner P, Ambros P, Martinsson T . Fine mapping of a tumour suppressor candidate gene region in 1p36.2-3, commonly deleted in neuroblastomas and germ cell tumours. Med Pediatr Oncol. 2001; 36(1):61-6. DOI: 10.1002/1096-911X(20010101)36:1<61::AID-MPO1016>3.0.CO;2-0. View